13:46 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Sarcoma In vitro , mouse and pig studies identified an RXR agonist that could help treat soft tissue sarcoma (STS). In silico screening of a small molecule library for compounds predicted to bind RXR,...
23:44 , Nov 19, 2018 |  BC Extra  |  Company News

Management tracks: Brickell, Genevant

Dermatology company Brickell Biotech Inc. (Boulder, Colo.) hired Robert Brown as CEO, effective Jan. 1. He will replace co-founder and CEO Reginald Hardy, who will remain on the board and serve as special adviser to...
17:26 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Brickell's sofpironium bromide meets in Phase IIb for hyperhidrosis

In October, Brickell Biotech Inc. (Boulder, Colo.) reported data from a double-blind, U.S. Phase IIb trial in 227 patients with primary axillary hyperhidrosis showing that 5%, 10% and 15% gel formulations of sofpironium bromide (BBI-4000)...
07:00 , Oct 27, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; colorectal cancer; cutaneous T cell lymphoma (CTCL) In vitro and cell culture studies identified agonists of RXR heterodimerization that could help treat colorectal cancer, CTCL and other cancers without causing the metabolic and...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

Sofpironium bromide: Phase IIb data

A double-blind, U.S. Phase IIb trial in 189 patients with primary axillary hyperhidrosis showed that BBI-4000 met the primary endpoint of a greater proportion of patients achieving a >=2-grade improvement in HDSS score from baseline...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Company News

Orca Pharmaceuticals, New York University, Brickell Biotech deal

Orca and the university granted Brickell exclusive, worldwide rights to a series of preclinical small molecule RAR-related orphan receptor C ( RORC ; RORgamma) inhibitors. Brickell will initially target the topical treatment of psoriasis. Brickell...
00:42 , Jul 9, 2015 |  BC Extra  |  Company News

Management tracks

Gastrointestinal play Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) named Troy Hamilton chief commercial officer. Hamilton was VP of product strategy and commercial lead in the GI business unit of Shire plc (LSE:SHP; NASDAQ:SHPG). Oncology company GTx Inc....
00:29 , May 19, 2015 |  BC Extra  |  Company News

Management tracks

Endocrine company Chiasma Inc. (Jerusalem, Israel) hired Mark Fitzpatrick as CFO, effective June 10. Fitzpatrick was CFO of rare disease company Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), where Chief Accounting Officer David Aubuchon will succeed him as...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

BBI-4000: Phase IIb started

Brickell began a double-blind, vehicle-controlled, U.S. Phase IIb trial to evaluate 3 dose levels of topical BBI-4000 once daily for 4 weeks in about 180 patients. Brickell Biotech Inc. , Miami, Fla.   Product: BBI-4000...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Financial News

Brickell Biotech completes venture financing

Brickell Biotech Inc. , Miami, Fla.   Business: Dermatology, Ophthalmic   Date completed: 2015-02-03   Type: Venture financing   Raised: $10 million   Investors: Company director; existing investors; company management; and other investors  ...